603108 润达医疗
2026/06 - 中期
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入3,193,710-7.98%6,998,5308,311,7809,147,37310,494,419
减:营业总成本3,128,161-10.99%7,099,4747,994,7838,651,9939,643,284
    其中:营业成本2,411,617-12.11%5,501,6286,203,4926,718,3717,557,067
               财务费用142,9878.62%273,516313,435316,682323,591
               资产减值损失(913)1,894.03%(208,737)(36,170)(34,500)(40,772)
公允价值变动收益------------
投资收益24,479-48.41%20,795109,821231,999137,048
    其中:对联营企业和合营企业的投资收益24,488-47.42%18,978108,488139,609138,057
营业利润553-101.07%(450,256)354,060646,803816,373
利润总额(10,526)-80.16%(460,637)345,542655,555819,651
减:所得税费用50,8959.64%57,514156,084212,920164,541
净利润(61,421)-38.26%(518,151)189,458442,636655,110
减:非控股权益26,44624.92%30,243134,177169,339237,364
股东净利润(87,867)-27.17%(548,394)55,281273,296417,746

市场价值指针
每股收益 (元) *-0.150-25.00%-0.9100.0900.4700.720
每股派息 (元) *------0.0300.1000.150
每股净资产 (元) *6.104-11.61%6.1947.1367.0606.519
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容